Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events.
J Dermatolog Treat
; 33(1): 354-360, 2022 Feb.
Article
em En
| MEDLINE
| ID: mdl-32319327
ABSTRACT
INTRODUCTION:
Data on real-world experiences for patients treated with ixekizumab is currently limited.OBJECTIVES:
Describe characteristics of ixekizumab-treated psoriasis patients and provide evidence of clinical outcomes using disease severity scores Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) in the real world.METHODS:
Chart review was performed for adult patients treated with ixekizumab at a single Canadian dermatology clinic (February 2017-August 2018). The cohort was stratified into responders (patients who remained on ixekizumab) and non-responders (patients who discontinued ixekizumab). Subgroup analyses were performed for responders to assess clinical improvement stratified by previous biologic exposure.RESULTS:
Thirty-eight patients were included (mean observational time 32 weeks). At baseline, mean PASI and BSA were 10.8 and 11.6%, respectively. Mean changes in PASI and BSA were -7.8 and -6.7%, respectively, at week 4. PASI 100 was achieved in 70% of patients. Significant differences in mean change of BSA were seen between bio-naïve and bio-experienced patients.CONCLUSION:
This analysis represents the first investigation of early clinical outcomes in a small cohort of Canadian patients treated with ixekizumab. Overall, complete and rapid skin clearance was observed. Future studies including more patients and longer follow-up time are crucial to confirm these findings.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Anticorpos Monoclonais Humanizados
Limite:
Adult
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Dermatolog Treat
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Canadá